Anti-Mouse CD309 (VEGFR2) [Clone DC101] — Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD309 (VEGFR2) [Clone DC101] — Purified in vivo PLATINUM™ Functional Grade
Product No.: V273
Clone DC101 Target VEGFR2 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names CD309, KDR, FLK-1, vascular endothelial growth factor receptor 2 Isotype Rat IgG1 κ Applications FA , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Recombinant full-length Mouse VEGFR2 protein Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 - 8°C Wet Ice Additional Applications Reported In Literature ? FA, WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity DC101 activity is directed against VEGFR-2. Background Vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR) play an essential role in angiogenesis1. There are three VEGFRs: VEGFR-1, VEGFR-2, and VEGFR-3. VEGFR-1 and VEGFR-2 are responsible for angiogenesis, and VEGFR-3 affects lymphogenesis. In the pathogenesis of diseases including diabetes mellitus, rheumatoid arthritis, and cancer, new blood vessel formation is highjacked. Changes at the VEGF/VEGFR-2 axis are particularly potent at allowing VEGF-induced proliferation, migration, and vascular endothelial cell differentiation during tumor angiogenesis. Additionally, VEGFR-2 is upregulated in tumor vascular endothelial cells, and VEGF levels are associated with poor prognosis and resistance to chemotherapy. Consequently, the VEGF/VEGFR axis is a prime anti-cancer target. DC101 greatly reduces melanoma tumor growth and cell proliferation in murine mouse models without adverse effects as well as promotes tumor vessel normalization2. Additionally, DC101 therapy enhances immune cell penetration of melanoma cells by increasing the proportion of CD19+ B cells, CD11c+ dendritic cells, and CD3+ and CD8+ T cells. DC101 treatment also increases expression of PD-1 and PD-L1 in CD45+ immune cells and tumors. Additionally, DC101 directly inhibits angiogenesis in vivo, and, in tumors, reduces xenograft tumor growth, decreases endothelial cells and microvessel density, and increases tumor cell apoptosis3. DC101 binds to an extracellular, ligand-binding domain on the amino-terminal of VEGFR-2, thereby blocking ligand binding and preventing VEGF165-induced receptor phosphorylation4. DC101 has been used in Cy5.5-, FITC, and HYNIC-labeled chitosan conjugates to study VEGFR-2 expression in ischemia5. Antigen Distribution VEGFR-2 is widely expressed by vascular endothelial cells, some vascular tumors, carcinomas, malignant melanomas, and lymphomas. Certain leukemia cells express functional VEGFR on the cell surface. Ligand/Receptor VEGF-A, VEGF-C, and VEGF-D splice isoforms NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone DC101 is most commonly used in vivo in mice to block signaling through vascular endothelial growth factor receptor 2 (VEGFR-2, also known as CD309/Flk-1/KDR), thereby inhibiting angiogenesis and suppressing tumor growth. Essential applications in vivo include:
Other reported but less common in vivo applications:
Application formats: Summary table:
DC101 is not used for immunohistochemistry or direct detection of VEGFR-2 in tissues in vivo but is instead employed for functional blockade or as a targeting moiety in modified therapeutic approaches. Commonly used antibodies or proteins combined with DC101 (an anti-VEGFR2 antibody) in the literature include:
Additional proteins or markers used in mechanistic or histological studies with DC101:
These combinations are designed to either enhance anti-angiogenic effect, test dual pathway inhibition, or assess impact on related biological markers in tumor models. Key findings from scientific literature citing clone DC101 focus on its role as a monoclonal antibody that targets VEGFR-2 (vascular endothelial growth factor receptor 2), resulting in significant antiangiogenic and antitumor effects. Essential findings include:
In summary, clone DC101 is widely cited for its robust antiangiogenic effects via VEGFR-2 inhibition, its capacity to modulate the tumor microenvironment, and its utility in combination therapeutic strategies, all of which underpin its importance as a tool in cancer research and preclinical therapy development. Dosing regimens of DC101—a monoclonal antibody targeting mouse VEGFR-2—vary considerably across mouse models depending on tumor type, experimental aim (e.g., antiangiogenesis, immune response modulation), and combination with other treatments. Key regimens and model differences:
Notable considerations:
In summary, DC101 dosing regimens are highly model-dependent, with variations in dose (from 150 μg to 40 mg/kg), schedule (single or repeated), and objectives (angiogenesis, immune modulation, etc.) according to the biology of the model and research goals. References & Citations1. Spratlin J. Curr Oncol Rep. 13(2):97-102. 2011. 2. Wang Z, Shi X, Zhao Y, et al. Biochem Biophys Res Commun. 661:10-20. 2023. 3. Prewett M, Huber J, Li Y, et al. Cancer Res. 59(20):5209-5218. 1999. 4. Patent EP1602668A1: https://patentimages.storage.googleapis.com/10/da/cb/f945064c422659/EP1602668A1.pdf 5. Lee CM, Kim EM, Cheong SJ, et al. J Biomed Mater Res A. 92(4):1510-1517. 2010. 6. Rockwell P, Neufeld G, Glassman A, et al. Mol Cell Differ. 3(1): 91–109. 1995. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
V176 | |
V179 | |
V173 | |
V181 | |
V182 | |
V183 | |
V184 | |
V177 | |
V178 | |
V273 |
